title: Mantle cell lymphoma: state of the art.
abstract: Mantle cell lymphoma (MCL) accounts for approximately 6% of all non-Hodgkin lymphomas (NHLs). The median age at diagnosis is 60 to 70 years, although MCL may occur in younger patients. Between 75% and 80% of patients are males. MCL usually presents as stage III/IV disease, and extranodal involvement is quite common, particularly in the bone marrow, blood, and gastrointestinal tract. Until recently, MCL was considered a disease with an overall poor prognosis. With the introduction of more aggressive induction chemotherapy regimens (especially those incorporating high-dose cytarabine), the anti-CD20 monoclonal antibody rituximab, and the more widespread use of consolidation with high-dose therapy and autologous stem cell rescue, outcomes have significantly improved. Some patients have even experienced long-term remissions. New insights into the biology of MCL, most prominently the role of the B-cell receptor pathway, have shed new light on treatment approaches for this disease. In this article, we will review current therapeutic approaches for MCL, as well as experimental ones.
authors: John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
authors: Alan P
authors: AP
authors: Skarbnik
authors: John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ.
authors: Andre H
authors: AH
authors: Goy
mesh_terms: D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D019233:Retreatment; D016896:Treatment Outcome